Alpha 2.0
Login Register
» Authors » Hong-Anh Thi Pham

Hong-Anh Thi Pham

Explore the profile of Hong-Anh Thi Pham including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 8
Citations 52
Followers 0
Related Specialties
Science
Oncology
General Medicine
Top 10 Co-Authors
Thanh-Thuy Thi Do
Hoai-Nghia Nguyen
Minh-Duy Phan
Hoa Giang
Le Son Tran
Kiet Truong Dinh
Binh Thanh Vo
Thanh-Truong Tran
Vu-Uyen Tran
Quynh-Tho Thi Nguyen
Published In
Sci Rep
Cancer Invest
PLoS One
Front Oncol
Heliyon
Affiliations
Soon will be listed here.
Recent Articles
1.
Assessing cybersecurity risks and prioritizing top strategies In Vietnam's finance and banking system using strategic decision-making models-based neutrosophic sets and Z number
Nguyen P, Pham T, Nguyen L, Pham H, Nguyen T, Vu T
Heliyon . 2024 Oct; 10(19):e37893. PMID: 39403491
The financial and banking system in Vietnam is currently confronted with a myriad of cybersecurity risks, a matter of paramount concern for the government, businesses, and individuals alike. These risks...
2.
Ultra-Deep Sequencing of Plasma-Circulating DNA for the Detection of Tumor- Derived Mutations in Patients with Nonmetastatic Colorectal Cancer
Nguyen H, Luong B, Tran D, Nguyen T, Ngo Q, Le L, et al.
Cancer Invest . 2021 Dec; 40(4):354-365. PMID: 34894952
Identification of tumor-derived mutation (TDM) in liquid biopsies (LB), especially in early-stage patients, faces several challenges, including low variant-allele frequencies, interference by white blood cell (WBC)-derived mutations (WDM), benign somatic...
3.
Liquid biopsy uncovers distinct patterns of DNA methylation and copy number changes in NSCLC patients with different EGFR-TKI resistant mutations
Nguyen H, Cao N, Nguyen T, Le K, Nguyen D, Nguyen Q, et al.
Sci Rep . 2021 Aug; 11(1):16436. PMID: 34385540
Targeted therapy with tyrosine kinase inhibitors (TKI) provides survival benefits to a majority of patients with non-small cell lung cancer (NSCLC). However, resistance to TKI almost always develops after treatment....
4.
Genetic profiling of Vietnamese population from large-scale genomic analysis of non-invasive prenatal testing data
Tran N, Vo T, Nguyen V, Tran N, Trinh T, Pham H, et al.
Sci Rep . 2020 Nov; 10(1):19142. PMID: 33154511
The under-representation of several ethnic groups in existing genetic databases and studies have undermined our understanding of the genetic variations and associated traits or diseases in many populations. Cost and...
5.
Ultra-Deep Massive Parallel Sequencing of Plasma Cell-Free DNA Enables Large-Scale Profiling of Driver Mutations in Vietnamese Patients With Advanced Non-Small Cell Lung Cancer
Tran L, Nguyen Q, Nguyen C, Tran V, Nguyen T, Le H, et al.
Front Oncol . 2020 Aug; 10:1351. PMID: 32850431
Population-specific profiling of mutations in cancer genes is of critical importance for the understanding of cancer biology in general as well as the establishment of optimal diagnostics and treatment guidelines...
6.
Actionable Mutation Profiles of Non-Small Cell Lung Cancer patients from Vietnamese population
Dang A, Tran V, Tran T, Pham H, Le D, Nguyen L, et al.
Sci Rep . 2020 Feb; 10(1):2707. PMID: 32066856
Comprehensive profiling of actionable mutations in non-small cell lung cancer (NSCLC) is vital to guide targeted therapy, thereby improving the survival rate of patients. Despite the high incidence and mortality...
7.
Evaluation of a Liquid Biopsy Protocol using Ultra-Deep Massive Parallel Sequencing for Detecting and Quantifying Circulation Tumor DNA in Colorectal Cancer Patients
Nguyen H, Tran D, Ngo Q, Pham H, Tran T, Tran V, et al.
Cancer Invest . 2020 Jan; 38(2):85-93. PMID: 31939681
The identification and quantification of actionable mutations are critical for guiding targeted therapy and monitoring drug response in colorectal cancer. Liquid biopsy (LB) based on plasma cell-free DNA analysis has...
8.
Ultra-deep massively parallel sequencing with unique molecular identifier tagging achieves comparable performance to droplet digital PCR for detection and quantification of circulating tumor DNA from lung cancer patients
Tran L, Pham H, Tran V, Tran T, Dang A, Le D, et al.
PLoS One . 2019 Dec; 14(12):e0226193. PMID: 31841547
The identification and quantification of actionable mutations are of critical importance for effective genotype-directed therapies, prognosis and drug response monitoring in patients with non-small-cell lung cancer (NSCLC). Although tumor tissue...